Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeResearchState Medicaid coverage 2026

Coverage teardown · 51 jurisdictions

State Medicaid GLP-1 coverage 2026 — the 12 states that pay for weight loss

As of January 2026, KFF counts 13 state Medicaid programs covering GLP-1 receptor agonists for obesity treatment under fee-for-service. Diabetes coverage is near-universal. The weight-loss landscape is volatile — four states dropped coverage after October 2025, and the federal Medicare Part D obesity carve-out remains blocked. Here is every jurisdiction, sourced.

Cartogram: 4 buckets, 51 jurisdictions

  • Covered for weight loss (12)
  • Limited / plan-dependent (4)
  • Dropped after Oct 2025 (4)
  • Diabetes-only (31)
State Medicaid GLP-1 coverage 2026 cartogramAK — Diabetes-onlyAKME — Diabetes-onlyMEHI — Diabetes-onlyHIWA — Diabetes-onlyWAMT — Diabetes-onlyMTND — Diabetes-onlyNDMN — Covered for weight lossMNWI — Covered for weight lossWIMI — Covered for weight lossMINY — Limited / plan-dependentNYVT — Diabetes-onlyVTNH — Dropped after Oct 2025NHOR — Limited / plan-dependentORID — Diabetes-onlyIDSD — Diabetes-onlySDIA — Diabetes-onlyIAIL — Diabetes-onlyILIN — Diabetes-onlyINOH — Diabetes-onlyOHPA — Dropped after Oct 2025PANJ — Limited / plan-dependentNJCT — Diabetes-onlyCTCA — Dropped after Oct 2025CANV — Diabetes-onlyNVWY — Diabetes-onlyWYNE — Diabetes-onlyNEMO — Covered for weight lossMOKY — Diabetes-onlyKYWV — Diabetes-onlyWVVA — Covered for weight lossVAMD — Diabetes-onlyMDDE — Covered for weight lossDERI — Covered for weight lossRIUT — Covered for weight lossUTCO — Diabetes-onlyCOKS — Covered for weight lossKSAR — Diabetes-onlyARTN — Covered for weight lossTNNC — Covered for weight lossNCDC — Diabetes-onlyDCMA — Limited / plan-dependentMAAZ — Diabetes-onlyAZNM — Diabetes-onlyNMOK — Diabetes-onlyOKLA — Diabetes-onlyLAMS — Covered for weight lossMSAL — Diabetes-onlyALGA — Diabetes-onlyGASC — Dropped after Oct 2025SCTX — Diabetes-onlyTXFL — Diabetes-onlyFL
See every state by bucket

Covered for weight loss · 12

DE, KS, MI, MN, MO, MS, NC, RI, TN, UT, VA, WI

Limited / plan-dependent · 4

MA, NJ, NY, OR

Dropped after Oct 2025 · 4

CA, NH, PA, SC

Diabetes-only · 31

AK, AL, AR, AZ, CO, CT, DC, FL, GA, HI, IA, ID, IL, IN, KY, LA, MD, ME, MT, ND, NE, NM, NV, OH, OK, SD, TX, VT, WA, WV, WY

Click any tile to see per-state Medicaid coverage notes + provider prices. Cartogram is rough geographic layout, not to scale — Alaska and Hawaii are boxed at left. Coverage data via our KFF-sourced tracker.

The coverage buckets, at-a-glance

State Medicaid GLP-1 coverage categorized into 4 buckets: covered, limited, dropped, and diabetes-only, with state counts and definitions.
BucketStatesMeaning for weight-loss Wegovy/Zepbound
Covered12GLP-1s covered for obesity treatment with prior authorization.
Limited4Diabetes coverage broad. Wegovy/Zepbound for weight loss alone plan-restricted or requires step-through.
Dropped4Weight-loss GLP-1 coverage ended amid budget pressure. Diabetes coverage continues.
Diabetes-only31Weight-loss GLP-1s not covered under Medicaid. Diabetes prescriptions covered.

Data as of 2026-07-17. Refresh triggered by KFF quarterly update or any state PDL change we detect.

Every state, by bucket

Weight-loss covered · 12 states

GLP-1s covered for obesity treatment with prior authorization.

Diabetes only + limited weight-loss · 4 states

Diabetes coverage broad. Wegovy/Zepbound for weight loss alone plan-restricted or requires step-through.

Dropped weight-loss coverage after Oct 2025 · 4 states

Weight-loss GLP-1 coverage ended amid budget pressure. Diabetes coverage continues.

Diabetes only · 31 states

Weight-loss GLP-1s not covered under Medicaid. Diabetes prescriptions covered.

Why coverage collapsed in 2025 (and what that means for 2026-2028)

Three forces converged. First, the Congressional Budget Office revised its 10-year federal Medicaid GLP-1 cost projection sharply upward — the October 2024 CBO report put expanded obesity coverage at roughly $35B over 10 years, but with real-world uptake ~40% higher than modeled, that number is now closer to $92B. Second, CMS declined in April 2025 to reinterpret the Social Security Act §1927(d)(2) carve-out that excludes “drugs when used for anorexia, weight loss, or weight gain” from mandatory Medicare Part D coverage — leaving states with no federal cost-sharing floor. Third, state Medicaid pharmacy budgets have absorbed a 200-400% year-over-year GLP-1 spending increase from 2023 to 2025 (KFF), and four states (CA, PA, NH, SC) pulled the plug in October 2025.

2026-2028 forecast, based on state budget filings + KFF tracking: two-to-four additional states are on the shortlist to drop weight-loss coverage in the FY27 budget cycle (Wisconsin, Rhode Island, and Michigan have all signaled active reconsideration). No state has publicly moved to add coverage. Federal action (whether Congress amends §1927 or CMS reverses the April 2025 rule) is the only realistic path to expansion.

If your state does not cover: three real paths

  1. Manufacturer savings cards. Wegovy is $499/mo cash via NovoCare regardless of insurance status; Zepbound is $349/mo (2.5 mg vial) or $499/mo (higher-dose vial) via LillyDirect. Neither requires prior authorization or Medicaid enrollment. Both are the fastest path for a patient whose state Medicaid does not cover weight-loss GLP-1s.
  2. Compounded semaglutide or tirzepatide. Licensed telehealth providers price at $99-249/mo for compounded 503A prescriptions. After the FDA compounding-shortage exception ended in October 2024, patient-specific compounding under 503A is legal but individualized — every provider must document a clinical need for a non-commercial formulation per patient. See the vetted-provider directory for currently compliant options.
  3. Commercial employer plans. If you have employer-sponsored insurance in addition to Medicaid, run the coverage checker against that plan — employer plans cover Wegovy or Zepbound at roughly 45% (Kaiser 2024 Employer Health Benefits Survey), materially higher than Medicaid weight-loss coverage. Insurance coverage checker handles the top 12 carriers.

Frequently asked

How many state Medicaid programs cover GLP-1s for weight loss in 2026?

Per KFF (Jan 2026), 13 state fee-for-service Medicaid programs cover GLP-1 receptor agonists for obesity. Glpverdict independently tracks 12 confirmed via state PDLs and press releases; the 13th is pending confirmation on our next refresh. Diabetes (T2D) coverage of Ozempic and Mounjaro is near-universal across all 50 states + DC.

Which states recently dropped GLP-1 weight-loss coverage?

Four states eliminated weight-loss Medicaid coverage after October 2025 amid budget pressure: California (Medi-Cal), Pennsylvania, New Hampshire, and South Carolina. North Carolina briefly dropped then reinstated coverage in December 2025.

What if my state does not cover Wegovy or Zepbound?

Three realistic paths: (1) manufacturer savings card — Wegovy $499/mo, Zepbound $349/mo cash — no insurance required; (2) compounded semaglutide or tirzepatide through a licensed telehealth provider, $99-249/mo; (3) if you have commercial employer insurance in addition to Medicaid, run the coverage checker against that plan since employer-sponsored coverage is often broader.

Is Medicaid coverage of GLP-1s expanding or contracting?

Contracting in most states, expanding in none as of mid-2026. The drivers are the CBO revised 10-year cost estimate for federal Medicaid GLP-1 spending (revised upward from $35B to $92B in 2024) and CMS declining in 2025 to reinterpret the Social Security Act §1927 obesity carve-out. Federal-level obesity coverage remains blocked; states adding coverage are doing so on their own dime.

Does the FDA-required prior authorization vary by state?

Yes — PA criteria are set at the state Medicaid level. Most covered states require documented BMI ≥30 (or ≥27 + comorbidity), a 3-6 month prior lifestyle-intervention attempt, and reauthorization every 12 months contingent on weight-loss milestone (typically ≥5% at 6 months). See your state PDL for exact criteria.

Sources

Editorial notes

  • Freshness: reviewed July 17, 2026. Refresh triggered by the KFF quarterly update or any confirmed state Medicaid PDL change.
  • Reconciliation: KFF national totals (13 covered states as of Jan 2026) sometimes lead our state-PDL tracker (currently 12 confirmed). We do not name the 13th state until we have a state-PDL or state Medicaid press-release citation.
  • Citation: journalists and researchers are welcome to cite this teardown — attribution to Glpverdict is the only requirement.
Does Medicaid cover Ozempic? State-by-state GLP-1 coverage in 2026